decoy20
decoy20: sourced relationships with 1 company · 1 clinical trial tracked.
decoy20 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could decoy20 → INDP affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Indaptus Therapeutics, Inc. (INDP) Solid Tumor, Adult | Phase 1/Phase 2 |
Clinical Trial Registry Records (1)
A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors
Primary endpoint: Number of Subjects with dose-limiting toxicities (DLTs)
Frequently asked questions
Which companies have sourced relationships with decoy20?
decoy20 has dated SEC/FDA relationship records for Indaptus Therapeutics, Inc..
How many clinical trials involve decoy20?
BioSniper tracks 1 clinical trial involving decoy20.